Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

Fighting antibiotic resistance: marrying new financial incentives to meeting public health goals.

Kesselheim AS, Outterson K.

Health Aff (Millwood). 2010 Sep;29(9):1689-96. doi: 10.1377/hlthaff.2009.0439.

2.

Should financial incentives be used to differentially reward 'me-too' and innovative drugs?

Pekarsky B.

Pharmacoeconomics. 2010;28(1):1-17. doi: 10.2165/11318770-000000000-00000. Review.

PMID:
20014872
3.

The role of the pharmaceutical industry in meeting the public health threat of antibacterial resistance.

Bergström R.

Drug Resist Updat. 2011 Apr;14(2):77-8. doi: 10.1016/j.drup.2011.01.005. Epub 2011 Apr 13. Review.

PMID:
21493123
4.

Novel approaches are needed to develop tomorrow's antibacterial therapies.

Spellberg B, Bartlett J, Wunderink R, Gilbert DN.

Am J Respir Crit Care Med. 2015 Jan 15;191(2):135-40. doi: 10.1164/rccm.201410-1894OE. Review.

5.

Antibiotic development: a victim of market forces?

Tillotson GS.

IDrugs. 2008 May;11(5):340-6. Review.

PMID:
18465675
6.

Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach.

Rex JH, Outterson K.

Lancet Infect Dis. 2016 Apr;16(4):500-5. doi: 10.1016/S1473-3099(15)00500-9. Review.

PMID:
27036356
7.

Impact of antibiotic restrictions: the pharmaceutical perspective.

Power E.

Clin Microbiol Infect. 2006 Aug;12 Suppl 5:25-34. Review.

8.

The need for new antibiotics.

Livermore DM.

Clin Microbiol Infect. 2004 Nov;10 Suppl 4:1-9. Review.

9.

The global need for effective antibiotics-moving towards concerted action.

Cars O, Hedin A, Heddini A.

Drug Resist Updat. 2011 Apr;14(2):68-9. doi: 10.1016/j.drup.2011.02.006. Epub 2011 Apr 1. Review.

PMID:
21444235
10.

Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America.

Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J.

Clin Infect Dis. 2009 Jan 1;48(1):1-12. doi: 10.1086/595011. Review.

PMID:
19035777
11.

Antibiotic policy.

Gyssens IC.

Int J Antimicrob Agents. 2011 Dec;38 Suppl:11-20. doi: 10.1016/j.ijantimicag.2011.09.002. Epub 2011 Oct 21. Review.

PMID:
22018989
12.

Antibiotics: the changing regulatory and pharmaceutical industry paradigm.

Bax R, Green S.

J Antimicrob Chemother. 2015 May;70(5):1281-4. doi: 10.1093/jac/dku572. Epub 2015 Jan 28. Review.

PMID:
25634991
13.

Resistance to antibiotics: are we in the post-antibiotic era?

Alanis AJ.

Arch Med Res. 2005 Nov-Dec;36(6):697-705. Review.

PMID:
16216651
14.

Clinical pharmacology of antimicrobial use in humans and animals.

Lathers CM.

J Clin Pharmacol. 2002 Jun;42(6):587-600. Review.

PMID:
12043947
15.

Moving from recommendation to implementation and audit: part 2. Review of interventions and audit.

Christiansen K, Carbon C, Cars O.

Clin Microbiol Infect. 2002;8 Suppl 2:107-28. Review.

16.

Selection of antibiotic-resistant pathogens in the community.

Yagupsky P.

Pediatr Infect Dis J. 2006 Oct;25(10):974-6. Review.

PMID:
17006309
17.

Antibiotic cycling and marketing into the 21st century: a perspective from the pharmaceutical industry.

Lavin BS.

Infect Control Hosp Epidemiol. 2000 Jan;21(1 Suppl):S32-5. Review.

PMID:
10654633
18.

Economics of antibiotic resistance.

Sipahi OR.

Expert Rev Anti Infect Ther. 2008 Aug;6(4):523-39. doi: 10.1586/14787210.6.4.523. Review.

PMID:
18662118
19.

New advances in antibiotic development and discovery.

Alekshun MN.

Expert Opin Investig Drugs. 2005 Feb;14(2):117-34. Review.

PMID:
15757391
20.

The global need for effective antibiotics: challenges and recent advances.

Högberg LD, Heddini A, Cars O.

Trends Pharmacol Sci. 2010 Nov;31(11):509-15. doi: 10.1016/j.tips.2010.08.002. Epub 2010 Sep 16. Review.

PMID:
20843562

Supplemental Content

Support Center